Datapoint: FDA Approves Genentech’s Lunsumio in Follicular Lymphoma

The FDA last month approved Genentech’s Lunsumio as a third-line treatment for follicular lymphoma, pitting the bispecific antibody against the CAR-T class: Bristol Myers Squibb’s Breyanzi, Gilead’s Yescarta and Novartis’ Kymriah. Genentech says Lunsumio has an advantage over its CAR-T rivals as an “off-the-shelf, accessible treatment option” that can be administered in an outpatient setting. Under the medical benefit, Breyanzi is currently the most advantaged of the three CAR-T therapies in the treatment of follicular lymphoma, holding covered or better status for 83% of all insured lives.

SOURCE: MMIT Analytics, as of 1/9/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 8

Datapoint: CMS Announces Special Enrollment Period for PHE Medicaid Coverage Losses

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 7

Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today